Plant extracts inhibit ADP-induced platelet activation in humans: Their potential therapeutic role as ADP antagonists

Purinergic Signalling

Volumn 10, Issue 2, 2014, Pages 233-239

  Jagroop, Indera Anita ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adenosine diphosphate (ADP); Antiplatelet drugs; Plant extract; Platelet; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AESCULUS HIPPOCASTANUM EXTRACT; ARC 69931; CAESALPINIA SAPPAN EXTRACT; CANGRELOR; CLOPIDOGREL; ELINOGREL; GONIOTHALAMUS EXTRACT; GONYSTYLUS VELUTINUS EXTRACT; LAVANDULA HYBRIDA EXTRACT; LICANIA PITTIERI EXTRACT; MITREPHORA EXTRACT; PLANT EXTRACT; PRASUGREL; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG EFFICACY; HEMOSTASIS; HUMAN; IC 50; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; DRUG EFFECTS; METABOLISM; PHYTOTHERAPY; PROCEDURES;

ADENOSINE DIPHOSPHATE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84901818596     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-013-9393-0     Document Type: Article

References (64)

1. Gachet C (2005) The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 10: 180-192.
2. Burnstock G (2011) Introductory overview of purinergic signalling. Front Biosci (Elite Ed) 3: 896-900.
3. Jagroop IA, Kakafika AI, Mikhailidis DP (2007) Platelets and vascular risk: an option for treatment. Curr Pharm Des 13: 1669-1683.
4. Pang L, Weiss MJ, Poncz M (2005) Megakaryocyte biology and related disorders. J Clin Invest 115: 3332-3338.
5. Hechler B, Cattaneo M, Gachet C (2005) The P2 receptors in platelet function. Semin Thromb Hemost 31: 150-161.
6. Cattaneo M (2005) The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 31: 168-173.
7. Kunapuli SP (2002) P2 receptors and platelet activation. Sci World J 13: 424-433.
8. Jagroop IA, Burnstock G, Mikhailidis DP (2003) Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 14: 15-20.
9. Mahaut-Smith MP, Jones S, Evans RJ (2011) The P2X1 receptor and platelet function. Purinergic Signal 7: 341-356.
10. Jennings LK (2009) Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102: 248-257.
11. Xiang YZ, Kang LY, Gao XM, Shang HC, Zhang JH, Zhang BL (2008) Strategies for antiplatelet targets and agents. Thromb Res 123: 35-49.
12. Barn K, Steinhubl SR (2012) A brief review of the past and future of platelet P2Y12 antagonist. Coron Artery Dis 23: 368-374.
13. Cattaneo M, Lecchi A (2007) Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5: 577-582.
14. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84: 891-896.
15. Bernlochner I, Sibbing D (2012) Thienopyridines and other ADP-receptor antagonists. Handb Exp Pharmacol 210: 165-198.
16. Kim L, Charitakis K, Swaminathan RV, Feldman DN (2012) Novel antiplatelet therapies. Curr Atheroscler Rep 14: 78-84.
17. Panak E, Maffrand JP, Picard-Fraire C, Vallée E, Blanchard J, Roncucci R (1983) Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 13: 1-54.
18. Packham MA, Mustard JF (2005) Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost 31: 129-138.
19. Cattaneo M, Podda GM (2010) State of the art of new P2Y12 antagonists. Intern Emerg Med 5: 385-391.
20. Gresele P, Agnelli G (2002) Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 23: 25-32.
21. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116: 2923-2932.
22. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
23. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US (2010) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121: 1188-1199.
24. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56: 1456-1462.
25. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047.
26. Norgard NB (2009) Cangrelor: a novel P2Y12 receptor antagonist. Expert Opin Investig Drugs 18: 1219-1230.
27. Oestreich JH (2010) Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 11: 340-348.
28. Patel PA, Lane B, Augoustides JG (2013) Progress in platelet blockers: the target is the P2Y12 receptor. J Cardiothorac Vasc Anesth 27: 620-624.
29. Collet JP, O'Connor S (2012) Clinical effects and outcomes with new P2Y12 inhibitors in ACS. Fundam Clin Pharmacol 26: 16-18.
30. Estrada O, Alvarado-Castillo C, Fernandez A, Lopez M, Romero-Vecchione E, Vasquez J et al (2009) Pomolic acid isolated from the leaves of Licania pittieri inhibits ADP- and epinephrine-induced platelet aggregation and has hypotensive effect on rats. Current Bioactive Compounds 5: 219-225.
31. Alvarado-Castillo C, Estrada O, Carvajal E (2012) Pomolic acid (PA), triterpenoid isolated from Licania pittieri, as a competitive antagonist of ADP-induced aggregation of human platelets. Phytomedicine 19: 484-487.
32. 2 synthesis: an in vitro study. Thromb Res 71: 227-236.
33. Barradas MA, O'Donoghue S, Mikhailidis DP (1992) Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo 6: 629-634.
34. Jagroop IA, Clathworthy I, Lewin J, Mikhailidis DP (2000) Shape change in human platelet: measurements with a channelyzer and visualisation by electron microscopy. Platelets 11: 28-32.
35. Jagroop IA, Mikhailidis DP (2001) Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens 15: 203-207.
36. Jagroop IA, Mikhailidis DP (2008) The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation. Clin Appl Thromb Hemost 14: 295-302.
37. Estrada O, González-Guzmán JM, Salazar-Bookaman M, Fernández AZ, Cardozo A, Alvarado-Castillo C (2011) Pomolic acid of Licania pittieri elicits endothelium-dependent relaxation in rat aortic rings. Phytomedicine 18: 464-469.
38. Barradas MA (1993) Serotonin and platelet studies in vascular disease. Doctor of Philosophy Thesis, p 74, University of London.
39. Chang Y, Huang SK, Lu WJ, Chung CL, Chen WL, Lu SH, Lin KH, Sheu JR (2013) Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets. J Biomed Sci 20: 4.
40. Hwang GS, Kim JY, Chang TS, Jeon SD, So DS, Moon CK (1998) Effects of brazilin on the phospholipase A2 activity and changes of intracellular free calcium concentration in rat platelets. Arch Pharm Res 21: 774-778.
41. Moharam BA, Jantan I, Jalil J, Shaari K (2010) Inhibitory effects of phylligenin and quebrachitol isolated from Mitrephora vulpina on platelet activating factor receptor binding and platelet aggregation. Molecules 15: 7840-7848.
42. Moharam BA, Jantan I, Fb A, Jalil J (2010) Antiplatelet aggregation and platelet activating factor (PAF) receptor antagonistic activities of the essential oils of five Goniothalamus species. Molecules 15: 5124-5138.
43. Ballabeni V, Tognolini M, Chiavarini M, Impicciatore M, Bruni R, Bianchi A, Barocelli E (2004) Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "grosso". Phytomedicine 11: 596-601.
44. Felixsson E, Persson IA, Eriksson AC, Persson K (2010) Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study. Phytother Res 24: 1297-1301.
45. Tiffany N, Boon H, Ulbricht C, Basch E, Bent S, Barrette EP, Smith M, Sollars D, Dennehy CE, Szapary P (2002) Horse chestnut: a multidisciplinary clinical review. J Herb Pharmacother 2: 71-85.
46. Siebert U, Brach M, Sroczynski G, Berla K (2002) Efficacy, routine effectiveness, and safety of horse chestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol 21: 305-315.
47. Kronberger L, Gölles J (1969) On the prevention of thrombosis with Aesculus extract. Med Klin 64: 1207-1209.
48. Marmot M (2001) Aetiology of coronary heart disease. BMJ 323: 1261-1262.
49. de Lange DW, Verhoef S, Gorter G, Kraaijenhagen RJ, van de Wiel A, Akkerman JW (2007) Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol Clin Exp Res 31: 1308-1314.
50. Ruf JC (1999) Wine and polyphenols related to platelet aggregation and atherothrombosis. Drugs Exp Clin Res 25: 125-131.
51. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-219.
52. Soleas GJ, Diamandis EP, Goldberg DM (1997) Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 11: 287-313.
53. Freedman JE, Parker C 3rd, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD (2001) Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 103: 2792-2798.
54. Pignatelli P, Lenti L, Pulcinelli FM, Catasca R, Saccani G, Germanò G, Marcoccia A, Silvestri MA, Ghiselli A, Violi F (2002) Red and white wine differently affect collagen-induced platelet aggregation. Pathophysiol Haemost Thromb 32: 356-358.
55. Clutton P, Folts JD, Freedman JE (2001) Pharmacological control of platelet function. Pharmacol Res 44: 255-264.
56. Ralevic V, Burnstock G (2003) Involvement of purinergic signaling in cardiovascular diseases. Drug News Perspect 16: 133-140.
57. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP (2004) The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 15: 117-125.
58. Erlinge D, Burnstock G (2008) P2 receptors in cardiovascular physiology and disease. Purinergic Signalling 4: 1-20.
59. Yun AJ, Bazar KA, Lee PY, Gerber A, Daniel SM (2005) The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. Med Hypotheses 64: 1073-1079.
60. Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH (2006) Green tea, the "Asian paradox," and cardiovascular disease. J Am Coll Surg 202: 813-825.
61. Imai K, Nakachi K (1995) Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 310: 693-696.
62. Kang WS, Lim IH, Yuk DY, Chung KH, Park JB, Yoo HS, Yun YP (1999) Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res 96: 229-337.
63. Islam MA (2012) Cardiovascular effects of green tea catechins: progress and promise. Recent Pat Cardiovasc Drug Discov 7: 88-99.
64. Cattaneo M (2007) Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 5: 45-55.